Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05553782 · ClinicalTrials.gov registry record · Early Phase 1
Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers
A Early Phase 1 study of Head and Neck Cancer and Squamous Cell Carcinoma of Head and Neck, sponsored by Brigham and Women's Hospital.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT05553782 is a Early Phase 1 study of Head and Neck Cancer and Squamous Cell Carcinoma of Head and Neck that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 30 participants, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (89% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT05553782, a Early Phase 1 study of Head and Neck Cancer and Squamous Cell Carcinoma of Head and Neck, is actively recruiting participants, sponsored by Brigham and Women's Hospital.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research study is studying the effect of different drugs as possible treatments for salivary and other head and neck cancers/ The name of the study intervention involved in this study is: \-- implantable microdevice
Conditions Studied
Interventions
- COMBINATION_PRODUCT Implantable Microdevice (IMD)
Study Locations (2)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-11-01 |
| Est. Completion | 2029-08-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05553782
The ClinicalTrials.gov registry entry for NCT05553782 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (89% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 1 intervention - of which Implantable Microdevice (IMD) is the first listed.
NCT05553782 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05553782 about?
NCT05553782 is a clinical study titled "Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers". This research study is studying the effect of different drugs as possible treatments for salivary and other head and neck cancers/ The name of the study intervention involved in this study is: \-- implantable microdevice
What is the current status of trial NCT05553782?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2023-11-01. Estimated completion is 2029-08-01.
What conditions does trial NCT05553782 study?
This clinical trial studies the following conditions: Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck, Salivary Gland Cancer, Adenoid Cystic Carcinoma of the Salivary Gland.
What interventions are being tested in trial NCT05553782?
The interventions under investigation include: Implantable Microdevice (IMD) (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05553782?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05553782 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Intraoral Hypothermia Device for Preserving Taste During Radiation
RECRUITING · Early Phase 1
-
Smoking Cessation Treatment for Head & Neck Cancer Patients
ACTIVE NOT RECRUITING · Early Phase 1
-
Pilot Study of Imatinib Cetuximab Combo for H & N Cancer
ACTIVE NOT RECRUITING · Early Phase 1
-
Pyrimethamine as an Inhibitor of NRF2 in HPV-unrelated Locally Advanced Head and Neck Squamous Cell Carcinoma
COMPLETED · Early Phase 1
-
Intratumoral Microdosing of TAK-981 in Head and Neck Cancer
COMPLETED · Early Phase 1
-
Curcumin Biomarker Trial in Head and Neck Cancer
COMPLETED · Early Phase 1
Explore more on PlainTrial
Head and Neck Cancer
All registered trials for this condition
Squamous Cell Carcinoma of Head and Neck
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.